Purpose: To determine if inhaled hypertonic saline (HS) accelerates airway mucociliary clearance (MCC) in well-controlled moderate to severe asthmatics.
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: July 2021
Participants: Non-smoking adults with well controlled moderate to severe asthma
Procedures (methods): After undergoing a general health screen, participants will undergo a lung transmission scan to create an image of the lungs. Participants will then inhale nebulized radiolabeled aerosol and sit in front of a gamma camera for 2 hours to measure clearance of radiolabeled particles from the lungs (procedure called gamma scintigraphy), which will be used to calculate baseline MCC. Participants will then inhale HS, with spirometry performed before and at regular intervals after HS to assess for clinically significant reductions in lung function. Vital signs and symptom questionnaires will be administered as well. If they are deemed tolerant to HS (i.e. no clinically significant deterioration in lung function, vital signs, or symptom questionnaire scores), participants will move forward to the next study visit. At the next visit, participants will again inhale nebulized HS and will undergo a gamma scintigraphy scan immediately after to measure the acute effects of HS on MCC. At a separate visit, participants will inhale nebulized HS and undergo gamma scintigraphy scan 4 hours later to measure prolonged effects of HS on MCC.
- Device: Hypertonic Saline
- 4 mL of 7% hypertonic saline
Arms, Groups and Cohorts
- Experimental: 7% Hypertonic Saline
- Subjects will inhale 4 mL of 7% hypertonic saline before having a Mucociliary Clearance (MCC) scan
Clinical Trial Outcome Measures
- Change in MCC from Baseline to Post Hypertonic Saline Inhalation
- Time Frame: Baseline, immediately after inhaled Hypertonic Saline, within approximately ’15′ minutes
- Effects of HS on MCC by testing
- Time Frame: Baseline, 4 hours after Hypertonic Saline
- The proportion of moderate to severe asthmatics who are deemed ‘intolerant’ to HS
- Time Frame: 30 minutes post-HS
- A persistent reduction in FEV1 of greater than or equal to 10% from that day’s baseline
Participating in This Clinical Trial
- Age 18-60 of both genders
- Moderate to severe asthma at baseline (determined by Step 3 therapy or greater or by asthma impairment) and well-controlled asthma at the time of enrollment, as determined by NHLBI Expert Panel Report 3 guidelines for diagnosis and treatment of asthma.
- Negative pregnancy test for females who are not s/p hysterectomy with oophorectomy.
- FEV1 (forced expiratory volume 1 sec) of at least 70% of predicted for age, sex, height, and race/ethnicity (without use of bronchodilating medications for 12 hours or long acting beta agonists for 24 hours).
Subjects who meet any of these criteria are not eligible for enrollment as study participants:
1. Clinical Contraindications:
Any chronic medical condition considered by the PI as a contraindication to the study including significant cardiovascular disease, diabetes, chronic renal disease, chronic thyroid disease, history of chronic infections/immunodeficiency, or history of tuberculosis Any acute infection requiring antibiotics within 4 weeks of study. Mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.
Medications which may impact the results of the study treatment, or may interfere with any other medications potentially used in the study (to include steroids, beta antagonists, non-steroidal anti-inflammatory agents) Active smoking to include e-cigarettes within 1 year of the study, or lifetime of > 10 pack-years of smoking Allergy/sensitivity to study drugs, or their formulations. History of intubation for asthma Unwillingness to use reliable contraception if sexually active (birth control pills/patch, condoms).
Viral upper respiratory tract infection within 4 weeks of challenge. Radiation exposure history in the past year that would cause the participant to exceed Federal radiation safety guidelines.
2. Pregnant women and children (< 18 years as this is age of majority in NC) will also be excluded since the risks associated with hypertonic saline inhalation to the fetus or child and the risk of radiation are unknown and cannot be justified.
3. Use of the following medications:
1. Systemic corticosteroids; subjects with systemic corticosteroid-dependent asthma will be excluded. All use of systemic steroids in the last year will be reviewed by a study physician.
2. Use of daily theophylline within the past month
3. Use of any immunosuppressant/immunomodulatory therapy within the preceding 12 months
4. Use of beta blocking medications
5. Receipt of LAIV (Live Attenuated Influenza Vaccine), also known as FluMist®, within the prior 30 days, or any vaccine within the prior 5 days
6. Multivitamins, Vitamin C or E or herbal medications in the 4 days prior to the treatment visit
7. Non-steroidal anti-inflammatory drugs in the 4 days prior to the treatment visit
8. Subjects must be able to withhold morning doses of maintenance inhalers on the treatment days, including long acting bronchodilators and inhaled corticosteroids.
4. Allergy/sensitivity to study drugs or their formulations: Known IgE-(Immunoglobulin E) mediated hypersensitivity to albuterol, diphenhydramine or corticosteroids.
5. Physical/laboratory indications:
1. Abnormalities on lung auscultation
2. Temperature > 37.8
3. Systolic BP >150 mm Hg or < 90 mm Hg or diastolic BP> 90 mm Hg or < 50
4. Oxygen saturation of < 93%
6. Inability or unwillingness of a participant to give written informed consent.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 60 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- University of North Carolina, Chapel Hill
- National Heart, Lung, and Blood Institute (NHLBI)
- Provider of Information About this Clinical Study
- Overall Official(s)
- David Peden, MD, MS, Principal Investigator, CEMALB
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.